Indian stock markets present attractive opportunities now. Investors with an 18-month outlook should consider deploying funds, especially i...

There was a time when having MNC stock was a must have in one's portfolio. They reason, they were very liberal at giving bonuses, dividend ...

After the IT bull of 2000, as a new set of Indian companies took the centerstage, a number of MNCs stocks lost their shine at least on the ...

At a time when the local market is assuming the centre stage of the growth strategy for Indian pharma companies, multinational drugmakers a...

Bear markets see sharp rallies. It is still time to stay on the sidelines, says the market expert.

FMCG, some private sector banks and even metal names are seeing corrections.

The deal may be valued at around $100 million and fits in with Aurobindo’s strategic road map of upping its presence in eastern Europe thro...

Clinton is generally perceived to be negative for pharma companies on the premise that she would try to curb the profits earned by the drug...

MNC and pharma cos have been always robust and some of the stocks always create value in portfolio, So you should use opportunities on lowe...

"The focus is more on domestic pharma company which have a base in domestic market as well as they have base," Mantri said.

Most MNCs have been facing heat due to fast expiring patents, challenges in new drug discovery and depleting product pipeline.

The rejection of the Glivec patent has added to pharma MNCs’ woes after a slew of measures in the past one year.

Opportunity in the pharma industry is huge so probably these parent companies may get more serious because they have been so far not taking...

"Well if you see MNC pharma stocks, I am bullish on MNC pharma stocks like Wyeth, Merck, Pfizer and Novartis. "

Acquisitions to help MNCs control nearly 50% of $9.5-billion domestic retail drug market: Analysts

World No 1 pharma company Pfizer on Wednesday announced a marketing tie-up with Rs 800-crore Ahmedabad-based Claris Lifesciences, that spec...

Domestic pharmaceutical shares have outperformed their multinational (MNC) counterparts in the last month, even as the MNCs have done some ...